$PULM
Pulmatrix Inc Stock $pulm

$pulm Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067777 Filed on November 13, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2014 Q1
Revenue	$0.00	$30.00K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.097M	$1.086M	$670.0K
YoY Change	317.11%	117.64%	157.69%
% of Gross Profit
Research & Development	$619.0K	$1.929M	$320.0K
YoY Change	56.71%	289.7%	60.0%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.716M	$2.624M	$990.0K
YoY Change	160.79%	163.98%	115.22%
Operating Profit	-$1.716M	-$2.594M
YoY Change	160.79%	160.97%
Interest Expense	$0.00	$7.885M
YoY Change
% of Operating Profit
Other Income/Expense, Net	$4.000K	$5.000K
YoY Change
Pretax Income	-$1.710M	-$1.710M	-$990.0K
YoY Change	159.09%	72.73%	115.22%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.712M	-$11.13M	-$990.0K
YoY Change	160.18%	1020.12%	115.22%
Net Earnings / Revenue		-37113.33%
Basic Earnings Per Share
Diluted Earnings Per Share	-$9.000M	-$9.000M	-$5.824M
COMMON SHARES
Basic Shares Outstanding	4.804M shares	4.804M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.57M	$12.88M	$15.57M
YoY Change	115600.0%	14211.11%	15470.0%
Cash & Equivalents	$451.0K	$753.0K	$15.57M
Short-Term Investments
Other Short-Term Assets	$50.00K	$20.00K	$1.000K
YoY Change	-80.0%	-90.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$831.0K	$13.17M	$15.57M
YoY Change	219.62%	4289.67%	15474.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$470.0K	$105.0K	$2.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$720.0K	$105.0K	$2.000K
YoY Change	-38.46%	-87.2%	-96.0%
TOTAL ASSETS
Total Short-Term Assets	$831.0K	$13.17M	$15.57M
Total Long-Term Assets	$720.0K	$105.0K	$2.000K
Total Assets	$1.551M	$13.27M	$15.58M
YoY Change	8.46%	1085.18%	10284.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$216.0K
YoY Change	-73.98%
Accrued Expenses	$3.544M	$570.0K	$410.0K
YoY Change	4962.86%	612.5%	310.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$43.46M	$575.0K	$947.0K
YoY Change	2288.08%	-56.77%	847.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.46M	$575.0K	$947.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$44.77M	$580.0K	$950.0K
YoY Change	2360.0%	-56.39%	850.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.9M	-$7.094M	-$3.669M
YoY Change
Common Stock	$23.14M	$480.00	$18.30M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$78.79M	$12.70M	$14.63M
YoY Change
Total Liabilities & Shareholders Equity	$1.551M	$13.27M	$15.58M
YoY Change	8.46%	1085.18%	10284.0%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2014 Q1
OPERATING ACTIVITIES
Net Income	-$1.712M	-$11.13M	-$990.0K
YoY Change	160.18%	1020.12%	115.22%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$1.310M	-$1.280M	-$1.390M
YoY Change	495.45%	24.27%	286.11%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$100.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$100.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-10.00K	16.95M
YoY Change	-100.0%	-100.94%	3584.78%
NET CHANGE
Cash From Operating Activities	-1.310M	-1.280M	-1.390M
Cash From Investing Activities	0.000	-100.0K	0.000
Cash From Financing Activities	0.000	-10.00K	16.95M
Net Change In Cash	-1.310M	-1.390M	15.56M
YoY Change	1537.5%	-4733.33%	15460.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.310M	-$1.280M	-$1.390M
Capital Expenditures	$0.00	-$100.0K	$0.00
Free Cash Flow	-$1.310M	-$1.180M	-$1.390M
YoY Change	495.45%	14.56%	286.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Operating Expenses OperatingExpenses	3434000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	994000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company’s deferred tax assets and the expense allocations relating to the Company’s operations prior to its deconsolidation from Oculus Innovative Sciences, Inc. (“Oculus” or “Former Parent”) on March 26, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1000	USD
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	20000	USD
CY2014Q1	us-gaap	Prepaid Rent PrepaidRent	2000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-994000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1715000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	9000	USD
CY2014Q3	us-gaap	Cash Cash	12880000	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	289000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	13169000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	105000	USD
CY2014Q3	us-gaap	Assets Assets	13274000	USD
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	573000	USD
CY2014Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	575000	USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	480	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18297535	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19792520	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7094000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	12699000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13274000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3859092	shares
	us-gaap	Net Income Loss NetIncomeLoss	-1471000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3425000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-994000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1710000	USD
CY2014Q3	rtgn	Working Capital WorkingCapital	12594000	USD
CY2014Q1	us-gaap	Prepaid Insurance PrepaidInsurance	0	USD
CY2014Q3	us-gaap	Prepaid Insurance PrepaidInsurance	228000	USD
CY2014Q3	us-gaap	Prepaid Rent PrepaidRent	2000	USD
CY2014Q1	rtgn	Other Prepaid Expenses And Current Assets OtherPrepaidExpensesAndCurrentAssets	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	865000	USD
CY2014Q3	rtgn	Other Prepaid Expenses And Current Assets OtherPrepaidExpensesAndCurrentAssets	39000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3000	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	289000	USD
CY2014Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	109000	USD
CY2014Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	77000	USD
CY2014Q1	rtgn	Accrued Director Compensation AccruedDirectorCompensation	50000	USD
CY2014Q3	rtgn	Accrued Director Compensation AccruedDirectorCompensation	41000	USD
	rtgn	Offering Cost Withheld From Proceeds OfferingCostWithheldFromProceeds	89000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	163000	USD
CY2014Q1	rtgn	Accrued Legal Fees AccruedLegalFees	183000	USD
CY2014Q3	rtgn	Accrued Legal Fees AccruedLegalFees	141000	USD
CY2014Q1	rtgn	Professional Fees Accrued Current ProfessionalFeesAccruedCurrent	53000	USD
CY2014Q3	rtgn	Professional Fees Accrued Current ProfessionalFeesAccruedCurrent	125000	USD
CY2014Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	15000	USD
CY2014Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	189000	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3145650	shares
	rtgn	Share Based Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm	P1Y6M
CY2014Q3	rtgn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Excercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExcercisableNumber	3047500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M10D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	332500	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	332500	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	27706	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.37
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.37
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y7M6D
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4650000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4804290	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4650000	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4804290	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1028000	USD
	rtgn	Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRights	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.79
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1593000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	199000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	133000	USD
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1394000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	332500	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.37
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2013Q3	us-gaap	Revenues Revenues	0	USD
CY2014Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	670000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1305000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	495000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	629000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	801000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2129000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	499000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1086000	USD
	us-gaap	Operating Expenses OperatingExpenses	1471000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	1715000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1471000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3434000	USD
CY2013Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0	USD
CY2014Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	103000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-103000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	535000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	rtgn	Investment From Related Party InvestmentFromRelatedParty	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	330000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2691000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15571000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12880000	USD
	rtgn	Gross Proceeds From Issuance Of Common Stock And Warrants GrossProceedsFromIssuanceOfCommonStockAndWarrants	1117000	USD
	rtgn	Offering Cost OfferingCost	252000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Ruthigen, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001574235
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	RTGN
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4804290	shares

Files In Submission

Name	View Source	Status
0001144204-14-067777-index-headers.html	Edgar Link	pending
0001144204-14-067777-index.html	Edgar Link	pending
0001144204-14-067777.txt	Edgar Link	pending
0001144204-14-067777-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtgn-20140930.xml	Edgar Link	completed
rtgn-20140930.xsd	Edgar Link	pending
rtgn-20140930_cal.xml	Edgar Link	unprocessable
rtgn-20140930_def.xml	Edgar Link	unprocessable
rtgn-20140930_lab.xml	Edgar Link	unprocessable
rtgn-20140930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
v391624_10q.htm	Edgar Link	pending
v391624_ex31-1.htm	Edgar Link	pending
v391624_ex31-2.htm	Edgar Link	pending
v391624_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PULM
Pulmatrix Inc Stock $pulm

2014 Q4 Form 10-Q Financial Statement

#000114420414067777 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM Pulmatrix Inc Stock $pulm

2014 Q4 Form 10-Q Financial Statement

#000114420414067777 Filed on November 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PULM
Pulmatrix Inc Stock $pulm